Proteome Sciences secures contract win with US biopharmaceutical firm
Proteome Sciences
3.51p
16:30 03/05/24
Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's mass spectrometry services for the analysis of samples for an on-going clinical trial.
FTSE AIM All-Share
771.53
17:14 03/05/24
Pharmaceuticals & Biotechnology
23,112.61
16:54 03/05/24
Proteome Sciences said on Thursday that the project will be provided utilising the Good Clinical Laboratory Practice accreditation obtained by the group specifically for this type of project.
The AIM-listed firm noted that the contract value was in excess of £500,000 and noted that it believes "a good proportion of the work" should be completed in the current financial year.
Chief commercial officer Richard Dennis said: "We have experienced good customer interest in our services in the first Quarter reflected by the considerable increase in customer contact and quotations across a broad range of projects. In this contract the client selected our targeted assay workflows with GCLP compliance as a quality standard specifically to monitor the performance of their investigational drug in their clinical trial. We expect the increased levels of interest in our services activities to continue through 2024 and look forward to further clinical trial projects."
As of 0945 BST, Proteome shares had skyrocketed 30.77% to 4.59p.
Reporting by Iain Gilbert at Sharecast.com